sub:assertion {
d:DB05259 v:identifier "DB05259" ;
v:namespace "drugbank" ;
v:uri "http://bio2rdf.org/drugbank:DB05259" ;
v:x-identifiers.org <
http://identifiers.org/drugbank/DB05259> ;
dv:drugbank-id "APRD00999" , "DB05259" ;
dv:x-atc <
http://bio2rdf.org/atc:L03AX13> ;
dv:x-cas <
http://bio2rdf.org/cas:147245-92-9> ;
dv:x-dpd <
http://bio2rdf.org/dpd:2233014> ;
dv:x-ndc <
http://bio2rdf.org/ndc:0088-1153-30> ;
dv:x-pharmgkb <
http://bio2rdf.org/pharmgkb:PA449760> ;
dv:x-wikipedia <
http://bio2rdf.org/wikipedia:Glatiramer_acetate> ;
dct:description "Glatiramer acetate consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. The average molecular weight of glatiramer acetate is 5,000-9,000 daltons. It is an immunomodulator, licensed in much of the world for reduced frequency of relapses in relapsing-remitting multiple sclerosis"@en ;
dct:identifier "drugbank:DB05259" ;
dct:title "Glatiramer Acetate"@en ;
a dv:Drug ;
rdfs:label "Glatiramer Acetate [drugbank:DB05259]"@en ;
rdfs:seeAlso <
http://www.drugbank.ca/drugs/DB05259> , <
http://www.drugs.com/cdi/glatiramer.html> , <
http://www.rxlist.com/cgi/generic/glatiramer.htm> .
}